Eris Lifesciences Limited (NSE:ERIS)
India · Delayed Price · Currency is INR 1,371.70
+6.50 (0.48%)
Jun 8, 2026, 3:29 PM IST
Eris Lifesciences Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Eris Lifesciences stock has a consensus rating of "Strong Buy" and an average price target of ₹1,697. The average 1-year stock price forecast is 23.69% higher than the current stock price, while the lowest is ₹1,435 (+4.61%) and the highest is ₹1,940 (+41.43%).
Price Target: ₹1,697 (+23.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Eris Lifesciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Financial Forecast
Revenue This Year
35.92B
from 31.15B
Increased by 15.33%
Revenue Next Year
41.34B
from 35.92B
Increased by 15.07%
EPS This Year
47.83
from 46.52
Increased by 2.82%
EPS Next Year
61.98
from 47.83
Increased by 29.59%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 37.1B | ||
| Avg | 35.9B | ||
| Low | 34.6B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 19.0% | ||
| Avg | 15.3% | ||
| Low | 11.1% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 47.83 | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 2.8% | ||
| Low | - |